Country for PR: United Kingdom
Contributor: PR Newswire Europe
Friday, June 05 2020 - 00:30
AsiaNet
Servier Completes the Acquisition of Symphogen
PARIS, June 4, 2020 /PRNewswire-AsiaNet/ --

Servier, an independent international pharmaceutical company, today announced 
that it has completed the acquisition of Symphogen A/S.

Symphogen will now function as Servier’s antibody center of excellence across 
multiple different therapeutic areas, including oncology. Symphogen, now a 
Servier subsidiary, will keep its operational autonomy and continue to rely on 
its experienced employees while maintaining its headquarters in Ballerup, 
Denmark. 

As part of the acquisition, Christophe Thurieau, Executive Director of Servier 
Research Institute, has been appointed Chief Executive Officer of Symphogen and 
Karin Garre, former Chief Operating Officer of Symphogen, has been appointed 
General Manager of Symphogen. Martin Olin, former Chief Executive Officer of 
Symphogen, will act as an external consultant to support this transition.  

Claude Bertrand, Executive Vice-President Research & Development at Servier, 
said: "The completion of this acquisition enables Servier to boost its antibody 
capabilities in oncology and its other therapeutic areas. The efficient 
antibody discovery and research platform of Symphogen will strengthen our R&D 
capabilities and pipeline in line with our aim of making life-saving treatments 
available to more patients across the world." 

Christophe Thurieau, Executive Director of Servier Research Institute and Chief 
Executive Officer of Symphogen, added: "In line with the values of Symphogen, 
we also strongly believe that innovation and collaboration are key to develop 
treatments for the benefit of patients. We are very pleased to welcome 
Symphogen as part of the Servier Group and look forward to further 
collaborating with the team on developing breakthrough antibody therapies for 
patients."

Karin Garre, General Manager of Symphogen, concluded: "The completion of this 
transaction marks a very exciting journey for Symphogen and Servier. Anchored 
in a pre-existing strategic collaboration, this acquisition supports the R&D 
strategy of Servier within antibodies thanks to the capabilities of Symphogen. 
As the two organizations share key values, I believe this unification is 
positioned for a great outcome going forward."  

PDF: https://mma.prnewswire.com/media/1175338/Servier_PDF_EN.pdf  
Logo: https://mma.prnewswire.com/media/1175327/Servier_Logo.jpg   

Contact: 
Sonia Marques, presse@servier.com, Tel. +33(0)1-55-72-40-21 / 
+33(0)7-84-28-76-13. 
Jean-Clément Vergeau, presse@servier.com, Tel. +33(0)1-55-72-46-16 / 
+33(0)6-79-56-75-96. 

Source: Servier
Translations

Japanese